Literature DB >> 33363038

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review.

Zheng Yan1, Shuna Yao1, Yanyan Liu1, Jianbo Zhang2, Peng Li3, Haiying Wang1, Junfeng Chu1, Shuang Zhao1, Zhihua Yao1.   

Abstract

The prognosis of patients with relapsed/refractory NK/T-cell lymphoma (NKTCL) is dismal. Immunotherapy has showed encouraging anti-tumor activity in patients with asparaginase-resistant NKTCL; however, only a portion of patients benefit and the median response duration is rather short. Treatment strategies have not been identified for immunotherapy-resistant NKTCL. We describe a patient with primary cutaneous NKTCL experienced disease progression after pegaspargase-based chemotherapy and PD-1 inhibitor (sintilimab)-based immunotherapy. Following a combined treatment of sintilimab and the HDAC inhibitor chidamide, the patient achieved a durable complete molecular response with mild toxicity. This case indicates that the combination of PD-1 inhibitor and HDAC inhibitor might be a treatment choice for immunotherapy-resistant NKTCL.
Copyright © 2020 Yan, Yao, Liu, Zhang, Li, Wang, Chu, Zhao and Yao.

Entities:  

Keywords:  NK/T-cell lymphoma; case report; chidamide; immunotherapy; immunotherapy resistance; sintilimab

Year:  2020        PMID： 33363038      PMCID： PMC7759664          DOI： 10.3389/fonc.2020.608304

Source DB:  PubMed          Journal:  Front Oncol        ISSN： 2234-943X            Impact factor:   6.244


  44 in total

1.  Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).

Authors:  Xiu-Wen Deng; Jun-Xin Wu; Tao Wu; Su-Yu Zhu; Mei Shi; Hang Su; Ying Wang; Xia He; Li-Ming Xu; Zhi-Yong Yuan; Li-Ling Zhang; Gang Wu; Bao-Lin Qu; Li-Ting Qian; Xiao-Rong Hou; Fu-Quan Zhang; Yu-Jing Zhang; Yuan Zhu; Jian-Zhong Cao; Sheng-Min Lan; Mei Dong; Shu-Nan Qi; Yong Yang; Ye-Xiong Li
Journal:  Radiother Oncol       Date:  2018-05-05       Impact factor: 6.280

2.  Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.

Authors:  Seok Jin Kim; Silvia Park; Eun Suk Kang; Joon Young Choi; Do Hoon Lim; Young Hyeh Ko; Won Seog Kim
Journal:  Ann Hematol       Date:  2014-08-02       Impact factor: 3.673

3.  Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.

Authors:  Diana Llopiz; Marta Ruiz; Lorea Villanueva; Tamara Iglesias; Leyre Silva; Josune Egea; Juan J Lasarte; Perrine Pivette; Véronique Trochon-Joseph; Bérangère Vasseur; Graham Dixon; Bruno Sangro; Pablo Sarobe
Journal:  Cancer Immunol Immunother       Date:  2018-12-13       Impact factor: 6.968

4.  The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States.

Authors:  John A Vargo; Arisha Patel; Scott M Glaser; Goundappa K Balasubramani; Rafic J Farah; Stanley M Marks; Sushil Beriwal
Journal:  Cancer       Date:  2017-04-05       Impact factor: 6.860

5.  PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Authors:  Benjamin J Chen; Bjoern Chapuy; Jing Ouyang; Heather H Sun; Margaretha G M Roemer; Mina L Xu; Hongbo Yu; Christopher D M Fletcher; Gordon J Freeman; Margaret A Shipp; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2013-05-14       Impact factor: 12.531

6.  Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type.

Authors:  R Suzuki; J Suzumiya; M Yamaguchi; S Nakamura; J Kameoka; H Kojima; M Abe; T Kinoshita; T Yoshino; K Iwatsuki; Y Kagami; T Tsuzuki; M Kurokawa; K Ito; K Kawa; K Oshimi
Journal:  Ann Oncol       Date:  2009-10-22       Impact factor: 32.976

7.  Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.

Authors:  Seok Jin Kim; Jing Quan Lim; Yurike Laurensia; Junhun Cho; Sang Eun Yoon; Ji Young Lee; Kyung Ju Ryu; Young Hyeh Ko; Youngil Koh; Duck Cho; Soon Thye Lim; Marie Beck Enemark; Francesco D'Amore; Mette Bjerre; Choon Kiat Ong; Won Seog Kim
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

8.  Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.

Authors:  Wing-yan Au; Dennis D Weisenburger; Tanin Intragumtornchai; Shigeo Nakamura; Won-Seog Kim; Ivy Sng; Julie Vose; James O Armitage; Raymond Liang
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113

9.  Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.

Authors:  Seok-Jin Kim; Jiyeon Hyeon; Inju Cho; Young Hyeh Ko; Won Seog Kim
Journal:  Cancer Res Treat       Date:  2018-07-20       Impact factor: 4.679

10.  Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.

Authors:  Kristin C Hicks; Massimo Fantini; Renee N Donahue; Angie Schwab; Karin M Knudson; Sarah R Tritsch; Caroline Jochems; Paul E Clavijo; Clint T Allen; James W Hodge; Kwong Y Tsang; Jeffrey Schlom; Sofia R Gameiro
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110
View more
  7 in total

1.  Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy.

Authors:  Yuan-Yuan Hao; Pan-Pan Chen; Xiang-Gui Yuan; Ai-Qi Zhao; Yun Liang; Hui Liu; Wen-Bin Qian
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

Review 2.  Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.

Authors:  Xi Chen; Wanchun Wu; Wenwen Wei; Liqun Zou
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

3.  Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report.

Authors:  Zhen-Dong He; Hai-Yan Yang; Sheng-Sheng Zhou; Man Wang; Qin-Li Mo; Feng-Xiang Huang; Zhi-Gang Peng
Journal:  World J Clin Cases       Date:  2022-02-06       Impact factor: 1.337

4.  Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory Sézary Syndrome: Case Series and A Literature Review.

Authors:  Chao Chen; Zhaorui Liu; Jie Liu; Wei Zhang; Daobin Zhou; Yan Zhang
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

5.  Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report.

Authors:  Juan Wang; Yong-Sheng Gao; Kun Xu; Xiao-Dong Li
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

6.  Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma.

Authors:  Mengya Zhong; Jinshui Tan; Guangchao Pan; Yuelong Jiang; Hui Zhou; Qian Lai; Qinwei Chen; Liyuan Fan; Manman Deng; Bing Xu; Jie Zha
Journal:  Front Oncol       Date:  2021-12-03       Impact factor: 6.244

Review 7.  Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review.

Authors:  Qing-Yuan Xu; Hai-Yan Yang; Mei-Wei Li; Zhen-Dong He; Hao-Yuan Hong; Zhi-Gang Peng
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.